Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
BSX vs SYK: Boston Scientific Down -53% YTD While Stryker Falls Just -11%

BSX vs SYK: Boston Scientific Down -53% YTD While Stryker Falls Just -11%

Key Takeaways

  • Both BSX and SYK are large medical technology companies, but their recent relative performance and market positioning have diverged sharply.
  • BSX has declined roughly 53% year to date amid pressure on its WATCHMAN and electrophysiology (EP) franchises, while SYK has fallen a far more moderate 11%.
  • SYK continues to pay a dividend and delivered mid-single-digit revenue growth, whereas BSX pays no dividend and saw growth slow to the low single digits.
  • In my view, SYK is the preferred name of the two, based on more consistent trend stability and stronger near-term positioning.
  • For deeper context on each company, explore BSX Major News, BSX Today's Price Move, SYK Major News, and SYK Today's Price Move.

Introduction

Investors evaluating medical device leaders frequently compare BSX (Boston Scientific) and SYK (Stryker). Both operate in cardiovascular, orthopedic, and surgical markets, yet their recent trajectories illustrate very different risk profiles. BSX has been re-priced sharply lower as two of its fastest-growing franchises lost momentum, while SYK has held up better despite its own operational disruptions. This stock comparison is relevant to growth investors seeking turnaround exposure and to more defensive investors focused on relative performance, dividend income, and market positioning. The sections below examine recent behavior, business drivers, and which name currently looks more attractive.

Why BSX Has Faced Headwinds

BSX (Boston Scientific) develops minimally invasive medical devices across interventional cardiology, cardiac rhythm management, electrophysiology (EP, the treatment of heart rhythm disorders), and urology. In recent weeks, the stock has traded near the low end of its 52-week range, down roughly 53% year to date, after a multi-year period of above-market growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The pullback reflects a slowdown concentrated in two franchises. The WATCHMAN left atrial appendage closure business has seen declining procedures as clinical evidence shifts patient referrals, while the EP segment—built around the FARAPULSE pulsed field ablation (PFA, a catheter technique for treating atrial fibrillation) platform—has ceded U.S. share to newer competitor technologies. A cybersecurity incident that temporarily halted manufacturing and shipping compounded these pressures. Management has lowered full-year guidance and signaled that 2027 is expected to be a trough year, with a return to stronger growth targeted for 2028 and beyond. The company also continues to invest through acquisitions, including its pending purchase of Penumbra.

How SYK Has Held Up Better

SYK (Stryker) designs and manufactures implants, robotics, surgical equipment, and neurotechnology across its MedSurg and Neurotechnology and Orthopaedics segments. The company's MedSurg business includes endoscopy, operating room equipment, and instruments. Over the recent period, SYK shares have been more resilient than BSX, declining roughly 11% year to date while still paying a dividend.

Recent results showed organic revenue growth near 8%, driven by strong MedSurg and capital equipment demand, along with continued adoption of its Mako robotic surgery system. The main soft spots were in large-joint orthopedics, where knee growth slowed to about 1% and hips declined, reflecting weaker procedure volumes tied to higher insurance deductibles and prior-authorization hurdles. SYK also faced a first-quarter cybersecurity incident and an enterprise software (SAP) implementation that disrupted commercial execution, prompting a modest reduction to its full-year outlook. Even so, the company's diversified portfolio and capital-equipment backlog have provided more stable footing than BSX's narrower growth drivers.

Head-to-Head Comparison

The clearest contrast between these two names is the distribution of growth and risk. BSX depends heavily on two high-growth franchises—WATCHMAN and EP—that are now facing competitive and clinical headwinds simultaneously, leaving roughly three-quarters of the portfolio to offset the drag. SYK, by contrast, draws on a broader base spanning robotics, capital equipment, trauma, and neurotechnology, which has helped cushion weakness in large-joint orthopedics.

On valuation, BSX trades at a lower forward earnings multiple after its steep decline, which some investors view as a potential turnaround setup—though that turnaround depends on product launches not expected until 2028. SYK carries a higher multiple but offers a dividend and stronger recent revenue growth. Both companies absorbed cybersecurity disruptions, yet SYK's diversification translated into smaller relative price damage. In terms of market sentiment, analyst consensus remains broadly constructive on SYK, while BSX faces a more uncertain near-term narrative. One thing that stands out here is how the broader exposure at SYK has supported more consistent performance.

Tickeron AI Verdict

Based on observable factors such as trend consistency, relative stability, catalysts, and market positioning, Tickeron's AI would currently favor SYK over BSX. SYK has demonstrated a more resilient price trend, maintained dividend support, and sustained healthier revenue growth despite its own operational disruptions. BSX, while offering a potential deep-value or turnaround profile, faces greater near-term uncertainty from franchise-specific headwinds and a delayed product-launch cadence. This assessment reflects a probabilistic, data-driven reading of current conditions rather than a definitive prediction, and conditions could shift as new earnings, product launches, or competitive developments emerge. I'm watching this closely as new data comes in.

Exploring Automated Trading Strategies

I often review Tickeron's Trending AI Robots page when looking for automated approaches that align with current market conditions. It highlights bots with strong recent statistics and risk profiles across different styles and timeframes, making it straightforward to compare options side by side.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BSX, SYK

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


BSX's Stochastic Oscillator is remaining in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for BSX crossed bullishly above the 50-day moving average on November 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.

Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 201 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 49 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.

The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 29 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.

BSX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -16%. POAS experienced the highest price growth at 158%, while LFWD experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
300 Boston Scientific Way
Phone
+1 508 683-4000
Employees
59000
Web
https://www.bostonscientific.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.